ArticleJournal of inflammation research2026
Exploring the Protective Mechanism of Xuebijing Injection Against Sepsis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Xuebijing (XBJ) injection is a traditional Chinese medicine (TCM) injection prepared using modern pharmaceutical techniques. Approved as a State Category II New Drug for sepsis, XBJ has demonstrated significant clinical efficacy in China. However, the bioactive components of XBJ and the mechanisms underlying its anti-sepsis effects remain to be fully elucidated. This study aimed to elucidate the regulatory network among herbs, compounds, genes, and signaling pathways. Methods: We conducted a network pharmacology analysis by integrating published RNA-sequencing data from the BioProject database and experimental evidence from 27 relevant studies identified in PubMed. And the anti-sepsis effects of XBJ and its main component, Hydroxysafflor Yellow A, were validated in a CLP-induced murine model. Results: Our results demonstrate that XBJ modulates 21 target genes through at least 18 of its bioactive compounds (e.g. Quercetin, Kaempferol). The majority of these genes, including IL6, TNF, and HMGB1, were down-regulated after XBJ treatment. Using a cecal ligation and puncture (CLP)-induced murine sepsis model, we demonstrated that by 24 hours post-operation, the survival rate in the XBJ-treated group was twice that of the PBS-treated group (66.7% vs. 33.3%). Finally, a comprehensive herb-compound-gene-pathway regulatory network was established to illustrate the potential mechanisms of action. Conclusion: In summary, this study reveals that XBJ may alleviate sepsis by modulating target genes via its compounds, primarily through anti-inflammatory and antioxidant pathways. This study provides a systematic elucidation of XBJ's anti-sepsis mechanism, and the research strategy established here offers a valuable framework for investigating the mechanisms of other complex traditional Chinese medicine formulae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.